The California Board of Pharmacy is accusing McKesson (MCK), the large pharmaceutical wholesaler, of selling excessive amounts of two controlled substances to a children’s hospital, the latest episode in which one of the biggest U.S. distributors has allegedly failed to sufficiently monitor shipments of such medicines.

In its complaint the board noted McKesson, in the fall of 2017, suddenly began supplying much larger quantities of Phenergan with codeine syrup, which is a combination narcotic and cough suppressant, and the Xanax anxiety medication, to the outpatient pharmacy at Rady Children’s Hospital of San Diego. But McKesson should have known such quantities are not typically distributed to pediatric patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy